IRIS UniCatt

De Cristofaro, Raimondo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.460
AS - Asia 5.431
EU - Europa 4.916
SA - Sud America 1.023
AF - Africa 145
OC - Oceania 17
Continente sconosciuto - Info sul continente non disponibili 10
Totale 18.002
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.284
SG - Singapore 2.438
DE - Germania 1.506
CN - Cina 1.269
BR - Brasile 844
SE - Svezia 815
IT - Italia 553
VN - Vietnam 515
UA - Ucraina 463
FR - Francia 419
GB - Regno Unito 244
IE - Irlanda 234
IN - India 228
FI - Finlandia 181
JP - Giappone 168
ID - Indonesia 164
PL - Polonia 157
BD - Bangladesh 147
RU - Federazione Russa 130
HK - Hong Kong 124
CA - Canada 90
AR - Argentina 78
TR - Turchia 74
IQ - Iraq 63
MX - Messico 49
NL - Olanda 48
ZA - Sudafrica 47
KR - Corea 38
BE - Belgio 26
EC - Ecuador 24
PK - Pakistan 22
IR - Iran 21
SA - Arabia Saudita 21
AT - Austria 20
ES - Italia 19
UZ - Uzbekistan 19
CO - Colombia 17
MA - Marocco 17
AU - Australia 16
VE - Venezuela 16
KE - Kenya 15
CL - Cile 14
EG - Egitto 14
LT - Lituania 14
RO - Romania 14
CI - Costa d'Avorio 13
PH - Filippine 13
TN - Tunisia 13
CZ - Repubblica Ceca 11
PY - Paraguay 11
AE - Emirati Arabi Uniti 10
DZ - Algeria 10
MY - Malesia 10
UY - Uruguay 10
IL - Israele 9
JO - Giordania 9
NP - Nepal 9
HN - Honduras 8
JM - Giamaica 8
AL - Albania 7
CH - Svizzera 7
MK - Macedonia 7
OM - Oman 7
KZ - Kazakistan 6
LV - Lettonia 6
SN - Senegal 6
BH - Bahrain 5
KG - Kirghizistan 5
KW - Kuwait 5
PE - Perù 5
AZ - Azerbaigian 4
BO - Bolivia 4
CR - Costa Rica 4
DO - Repubblica Dominicana 4
ET - Etiopia 4
EU - Europa 4
GR - Grecia 4
HU - Ungheria 4
NO - Norvegia 4
PS - Palestinian Territory 4
TT - Trinidad e Tobago 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AM - Armenia 3
BG - Bulgaria 3
HR - Croazia 3
LU - Lussemburgo 3
PA - Panama 3
PT - Portogallo 3
SY - Repubblica araba siriana 3
TH - Thailandia 3
BA - Bosnia-Erzegovina 2
CY - Cipro 2
DK - Danimarca 2
LK - Sri Lanka 2
MM - Myanmar 2
PR - Porto Rico 2
RS - Serbia 2
SV - El Salvador 2
XK - ???statistics.table.value.countryCode.XK??? 2
A1 - Anonimo 1
Totale 17.979
Salva come PNG Salva come JPEG
Città #
Singapore 1.250
Ashburn 767
San Jose 681
Chandler 657
Jacksonville 250
Beijing 240
Dublin 225
San Mateo 212
Nanjing 161
Ho Chi Minh City 160
Los Angeles 154
Tokyo 152
Jakarta 146
Lauterbourg 146
New York 144
Wilmington 143
Warsaw 133
Hefei 130
Hanoi 127
Milan 117
Ann Arbor 112
St Louis 107
Hong Kong 103
Boston 99
Woodbridge 99
Munich 89
Chicago 88
Dearborn 88
Houston 86
Moscow 81
Frankfurt am Main 80
Fairfield 77
Lawrence 71
Pune 71
Redwood City 71
Seattle 71
São Paulo 69
Nürnberg 65
Dallas 61
Santa Clara 59
Helsinki 57
Princeton 55
Cattolica 53
Rome 53
Nanchang 52
Council Bluffs 50
Marseille 46
Redmond 44
Buffalo 43
London 42
The Dalles 40
Izmir 36
Rio de Janeiro 35
Seoul 33
University Park 33
Boardman 32
Bremen 32
Kent 32
Hangzhou 31
Orem 31
Da Nang 29
Paris 28
Augusta 27
Kunming 27
Tianjin 27
Nuremberg 26
Mountain View 25
Baghdad 24
Mexico City 24
Phoenix 24
Turku 24
Brussels 23
Johannesburg 23
Changsha 22
Hyderabad 22
Norwalk 22
Shenyang 21
Detroit 20
Brooklyn 19
San Francisco 19
Shanghai 19
Toronto 19
Zhengzhou 19
Amsterdam 18
Chennai 18
Guangzhou 18
Haiphong 18
Bareggio 17
Denver 17
Hebei 17
Jiaxing 17
Montreal 17
Atlanta 15
Belo Horizonte 15
Brasília 15
Cambridge 15
Curitiba 15
Tashkent 15
Kraków 14
Nairobi 14
Totale 9.280
Salva come PNG Salva come JPEG
Nome #
The oxidative modification of von Willebrand factor is associated with thrombotic angiopathies in diabetes mellitus. 336
Portal vein thrombosis: insight into physiopathology, diagnosis, and treatment 333
Qualitative and quantitative modifications of von willebrand factor in patients with essential thrombocythemia and controlled platelet count 333
Pathogenesis Of Portal Vein Thrombosis In Liver Cirrhosis: The Role of the ADAMTS13/VWF Unbalance 289
Novel path to IL-6 trans-signaling through thrombin-induced soluble IL-6 receptor release by platelets 226
The Type 2b P.R1306w Natural Mutation Of Von Willebrand Factor Dramatically Enhances The Multimer Sensitivity To Shear Stress 191
Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development 190
Glycaemic variability affects ischaemia-induced angiogenesis in diabetic mice. 189
Presence of portal vein thrombosis in liver cirrhosis is strongly associated with low levels of ADAMTS-13: a pilot study 184
Kinetic study of von Willebrand factor self-aggregation induced by ristocetin 179
Prostaglandin E2 differentially modulates human platelet function through the prostanoid EP2 and EP3 receptors 178
Carbamazepine interaction with direct oral anticoagulants: help from the laboratory for the personalized management of oral anticoagulant therapy 171
Noncanonical type 2B von Willebrand disease associated with mutations in the VWF D9D3 and D4 domains 171
β2-Glycoprotein I Binds Thrombin and Selectively Inhibits the Enzyme Procoagulant Functions 165
Effect of fibrinogen concentration on the velocity of platelet aggregation. 163
Formation of methionine sulfoxide by peroxynitrite at position 1606 of von Willebrand factor inhibits its cleavage by ADAMTS-13. A new prothrombotic mechanism associated with oxidative stress 162
Pseudo-acquired vWD in essential thrombocythemia: the role of platelets 156
The D173G mutation in ADAMTS-13 causes a severe form of congenital thrombotic thrombocytopenic purpura. A clinical, biochemical and in silico study 156
Safety and efficacy of damoctocog alfa pegol prophylaxis in patients with severe haemophilia A: Results of an interventional, post-marketing study 154
Cyclooxygenase-2 (COX-2) inhibition constrains indoleamine 2,3-dioxygenase 1 (IDO1) activity in acute myeloid leukaemia cells 154
ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation: the (ORIGAMI) study 154
Hyposialylation of neprilysin possibly affects its expression and enzymatic activity in hereditary inclusion-body myopathy muscle 151
Oxidized von Willebrand factor is efficiently cleaved by serine proteases from primary granules of leukocytes: divergence from adamts-13 147
Congenital prothrombin deficiency: an update 147
Evaluation of the thiobarbituric acid test (TBA test) properties for the determination of glycosylated hemoglobins by comparison with chromatography and isoelectrofocusing. 146
An old drug for a new application: carbazochrome-sodium-sulfonate in HHT 146
Does chronic oral anticoagulation reduce in-hospital mortality among COVID-19 older patients? 144
Molecular Aggregation of Marketed Recombinant FVIII Products: Biochemical Evidence and Functional Effects 141
Structural and funtional mapping of the thrombin domain involved in the binding to the platelet glycoprotein Ib 139
Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma 139
Oral anticoagulants in fragile patients with percutaneous endoscopic gastrostomy and atrial fibrillation: the ORIGAMI pilot investigation 138
MORE EARLY BLEEDS ASSOCIATED WITH HIGH BASELINE DIRECT ORAL ANTICOAGULANT LEVELS IN ATRIAL FIBRILLATION: THE MAS STUDY 137
Effects of low-dose rivaroxaban combined with low-dose aspirin versus low-dose aspirin alone on in vivo platelet activation, endothelial function and inflammation in type 2 diabetes patients with stable atherosclerotic disease: the RivAsa randomized, crossover study 136
ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation: the (ORIGAMI) study 136
Haemostatic system in inflammatory bowel diseases: new players in gut inflammation. 135
Molecular Aggregation of Marketed Recombinant FVIII Products: Biochemical Evidence and Functional Effects. 135
PURIFICATION OF THE ISOLATED BETA-CHAIN OF ADULT HUMAN-HEMOGLOBIN FROM ITS POST-TRANSLATIONAL MODIFICATION 134
Diagnosis and management of cerebral venous sinus thrombosis in children: a single-center retrospective analysis 134
Detection of Platelet-Activating Antibodies Associated with Vaccine-Induced Thrombotic Thrombocytopenia by Flow Cytometry: An Italian Experience 133
Hemophilia A and von Willebrand deficiency: therapeutic implications 130
From angiotensin-converting enzyme 2 disruption to thromboinflammatory microvascular disease: A paradigm drawn from COVID-19 130
Aims: The ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation (ORIGAMI) study investigates the safety and efficacy of Edoxaban administered via PEG in patients with atrial fibrillation and a clinical indication for a long-term anticoagulation. Design: In this prospective, single-centre observational study, 12 PEG-treated patients with indication to anticoagulation will receive edoxaban via PEG and will be followed up to 6 months. Plasma antifactor Xa activity and edoxaban concentrations will be assessed. Thromboembolic (ischaemic stroke, systemic embolism, venous thromboembolism) and bleeding events (Bleeding Academic Research Consortium and Thrombolysis in Myocardial Infarction) will be recorded at 1 and 6 months. Preliminary results: A retrospective analysis of five atrial fibrillation cases undergoing PEG implantation at our Institution who received edoxaban via PEG showed plasma anti-FXa levels at a steady state of 146 ± 15 ng/ml, without major adverse event at a mean follow-up of 6 months. Conclusion: ORIGAMI prospectively investigates PEG-administration of edoxaban in PEG-treated patients requiring long-term anticoagulation. Our preliminary retrospective data support this route of DOAC administration. 130
Direct oral anticoagulants and therapeutic adherence: do not let your guard down 129
high performance liquid chromatography in protein sequence determination. 128
Hexopeptidase high performance liquid chromatography (HPLC) mapping and is application to peptide sequence strategies. 127
Ristocetin-induced self-aggregation of von Willebrand factor. 124
Defective platelet responsiveness to thrombin and protease-activated receptors agonists in a novel case of gray platelet syndrome: correlation between the platelet defect and the alpha-granule content in the patient and four relatives 121
Carbamazepine interaction with direct oral anticoagulants: help from the laboratory for the personalized management of oral anticoagulant therapy 121
SPONTANEOUS DEEP HEMATOMAS IN 2 PATIENTS WITH MYELOFIBROSIS - EVIDENCE OF PLATELET MEMBRANE GLYCOPROTEIN MODIFICATIONS 120
Immune toilerance by intermittent factor VIII boluses in two hemophilia A patients 119
Another family with IGPS 119
Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma 119
Cystic fibrosis transmembrane conductance regulator (CFTR) expression in human platelets: impact on mediators and mechanisms of the inflammatory response 118
β2 -Glycoprotein I binds to thrombin and selectively inhibits the enzyme procoagulant functions 118
Mechanochemistry of von Willebrand factor 118
Increased platelet-fibrinogen affinity in patients with myeloproliferative disorders. 117
D-dimer and reduced-dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study 116
Heparin versus prostacyclin in continuous hemodiafiltration for acute renal failure: effects on platelet function in the systemic circulation and across the filter 116
Proteolytic Processing of Von Willebrand Factor by Adamts13 and Leukocyte Proteases 116
High-mobility group box-1 protein promotes angiogenesis after peripheral ischemia in diabetic mice through a VEGF-dependent mechanism 115
Biochemical properties of indoleamine 2,3-dioxygenase: from structure to optimized design of inhibitors 115
Effects of coagulation factors on bone cells and consequences of their absence in haemophilia a patients 114
Inherited macrothrombocytopenia with distinctive platelet ultrastructural and functional features 114
The effect of shear stress on protein conformation: Physical forces operating on biochemical systems: The case of von Willebrand factor. 114
Increased von Willebrand factor levels in polycythemia vera and phenotypic differences with essential thrombocythemia 114
Homocysteinemia is inversely correlated with platelet count and inversely correlated with sE-and sP-selectin levels in females homozygous for C677T methylenetetrahydrofolate reductase 113
Evaluation of assay methods to measure plasma ADAMTS13 activity in thrombotic microangiopathies. 113
Real-World Data on Effectiveness and Safety of First-Line Use of Caplacizumab in Italian Centers for the Treatment of Thrombotic Thrombocytopenic Purpura: The Roscapli Study 112
On-pump Cardiac Surgery Enhances Platelet Renewal and Impairs Aspirin Pharmacodynamics: Effects of Improved Dosing Regimens 112
Thrombin interaction with platelet GpIB: role of the heparin binding domain. 111
The dominant-negative von Willebrand factor gene deletion p.P1127_C1948delinsR: molecular mechanism and modulation. 111
Thrombin-thrombomodulin interaction: energetics and potential role of water as an allosteric effector. 111
Allosteric equilibria in the binding reaction of fibrinogen to platelets. 111
Design organization and clinical processes around patient characteristics: Evidence from a multiple case study of Hemophilia 110
Congenital prothrombin deficiency 108
Molecular characterization of in-frame and out-of-frame alternative splicings in coagulation factor XI pre-mRNA 108
Oral Squamous Cell Carcinoma-Associated Thrombosis: What Evidence? 107
Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters: the 2013 AICE survey 106
Portal vein thrombosis occurrence in a cirrhotic patient during treatment with rivaroxaban 106
ADAMTS-13/von Willebrand factor ratio: A prognostic biomarker for portal vein thrombosis in compensated cirrhosis. A prospective observational study 106
Measurement of extended half-life recombinant FVIII molecules: In vitro and ex vivo evidence of relevant assay discrepancies 105
Relevance of chloride binding to von Willebrand factor in type 2B von Willebrand disease patients 105
Extended coagulation profile of children with Long Covid: a prospective study 104
Plasma protein oxidation is associated with an increase of procoagulant markers causing an imbalance between pro- and anticoagulant pathways in healthy subjects 104
Current Choices and Management of Treatment in Persons with Severe Hemophilia A without Inhibitors: A Mini‐Delphi Consensus 101
Binding of human alpha-thrombin to platelet GpIb: energetics and functional effects. 99
Placental-derived PGI2 inhibits cord blood platelet function 98
Placental derived PGI2 inhibits cord platelet function:possible role of PGI in THR transient hyporeactivity of newborn platelets 98
Heparin versus prostacyclin in continuous hemodiafiltration for acute renal failure: effects on platelet function in the systemic circulation and across the filter 98
The p.P1127S pathogenic variant lowers von Willebrand factor levels through higher affinity for the macrophagic scavenger receptor LRP1: Clinical phenotype and pathogenic mechanisms 97
The linkage between binding of the C-terminal domain of hirudin and amidase activity in human alpha-thrombin 97
Mechanistic studies on ADAMTS13 catalysis. 97
KINETIC ASPECTS OF RELEASE OF FIBRINOPEPTIDES AP AND AY BY HUMAN ALPHA-THROMBIN 96
Real-World Data on Effectiveness and Safety of First-Line Use of Caplacizumab in Italian Centers for the Treatment of Thrombotic Thrombocytopenic Purpura: The Roscapli Study 94
Measurement of plasma fibrinogen concentration by the prothrombin-time-derived method: applicability and limitations. 94
Wiskott-Aldrich syndrome: report of an autosomal dominant variant 94
Sustained safe and effective anticoagulation using Edoxaban via percutaneous endoscopic gastrostomy 94
Real-World Data on Effectiveness and Safety of First-Line Use of Caplacizumab in Italian Centers for the Treatment of Thrombotic Thrombocytopenic Purpura: The Roscapli Study 93
Fibrinogen-elongated gamma chain inhibits thrombin-induced platelet response, hindering the interaction with different receptors 93
The expanding spectrum of PRPS1-associated phenotypes: three novel mutations segregating with X-linked hearing loss and mild peripheral neuropathy 93
Totale 13.473
Salva come PNG Salva come JPEG
Categoria #
all - tutte 76.009
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 76.009
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202133 0 0 0 0 0 0 0 0 0 0 0 33
2021/20221.124 83 114 24 62 64 35 34 173 60 54 206 215
2022/20231.973 264 318 165 259 155 233 80 171 230 26 56 16
2023/20241.163 41 316 30 78 49 203 66 61 17 39 102 161
2024/20252.597 58 42 197 98 191 89 59 121 419 317 554 452
2025/20267.130 1.071 306 452 718 1.068 352 1.286 357 443 567 304 206
Totale 18.182